Toll Like Receptor 8 CD288 or TLR8 Pipeline Review, H1 2018
Summary
According to the recently published report 'Toll Like Receptor 8 CD288 or TLR8 Pipeline Review, H1 2018'; Toll Like Receptor 8 CD288 or TLR8 pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 8 CD288 or TLR8 Tolllike receptor 8 is a protein encoded by the TLR8 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NFkappaB activation, cytokine secretion and the inflammatory response.
The report 'Toll Like Receptor 8 CD288 or TLR8 Pipeline Review, H1 2018' outlays comprehensive information on the Toll Like Receptor 8 CD288 or TLR8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Toll Like Receptor 8 CD288 or TLR8 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 5, 6, 1 and 4 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Musculoskeletal Disorders, Dermatology, Gastrointestinal and Respiratory which include indications Cutaneous TCell Lymphoma, Solid Tumor, Colorectal Cancer, Melanoma, Renal Cell Carcinoma, Systemic Lupus Erythematosus, Actinic Solar Keratosis, Allergic Rhinitis, Arthritis, Autoimmune Disorders, Breast Cancer, Crohn's Disease Regional Enteritis, Dermatomyositis, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatitis B, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, NonSmall Cell Lung Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sarcomas, Sicca Syndrome Sjogren, SystemicOnset Juvenile Idiopathic Arthritis Still Disease, Transitional Cell Cancer Urothelial Cell Cancer, Transitional Cell Carcinoma Urothelial Cell Carcinoma, Ulcerative Colitis and Warts.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 CD288 or TLR8
The report reviews Toll Like Receptor 8 CD288 or TLR8 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Toll Like Receptor 8 CD288 or TLR8 targeted therapeutics and enlists all their major and minor projects
The report assesses Toll Like Receptor 8 CD288 or TLR8 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Toll Like Receptor 8 CD288 or TLR8 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 CD288 or TLR8
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 CD288 or TLR8 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope